Skip to main content
SpringerLink
Log in

Myelodysplastische Syndrome

  • Chapter
Therapiekonzepte Onkologie

  • 56 Accesses

Zusammenfassung

Heterogene Gruppe von Erkrankungen mit den gemeinsamen Charakteristika einer monoklonalen Hämatopoese mit normo- oder hyperzellulärem Knochenmark und peripherer Zytopenie einer oder mehrerer hämatopoetischer Zellreihen aufgrund einer Störung von Proliferation und Differenzierung pluripotenter Stammzellen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aul C, Gattermann N, Schneider W (1992) Age — related incidence and other epidemiological aspects of myelodysplastic syndromes. Brit J Haemat 82: 358367

    Google Scholar 

  2. Crane M, Keating MJ (1991) Exposure history in acute nonlymphocytic leukemia patients with a priori preleukemic condition. Cancer 67: 2211–2214

    Article  PubMed  CAS  Google Scholar 

  3. Pedersen-Bjergaard J (1992) Radiotherapy-and chemotherapy-induced myelodysplasia and acute myeloid leukemia. A review. Leukemia Res 16: 6165

    Google Scholar 

  4. Ratain MJ, Rowley JD (1992) Therapy-related acute myeloid leukemia secondary to inhibitors of toposiomerase II: from the bedside to the target genes. Ann Oncol 3: 107–111

    Article  PubMed  CAS  Google Scholar 

  5. Mecucci C, van den Berghe H (1992) Cytogenetics. Hematol Oncol Clin North Am 6: 523–541

    CAS  Google Scholar 

  6. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1982) French-American-British (FAB) cooperative group. Proposals for the classification of myelodysplastic syndromes. Br J Haemat: 189–199

    Google Scholar 

  7. Goasguen JE, Bennett JM (1992) Classification and morphologic features of the myelodysplastic syndromes. Sem Oncol 19: 4–13

    CAS  Google Scholar 

  8. Wörmann B (1993) Myelodysplastisches Syndrom und sekundäre Leukämie. Internist 34: 518–525

    PubMed  Google Scholar 

  9. Mufti GJ (1992) A guide to risk assessment in the primary myelodysplastic syndrome. Hematol Oncol Clin of North Am 6: 587–606

    CAS  Google Scholar 

  10. List AF, Garewal HS, Sandberg AA (1990) The myelodysplastic syndromes: biology and implications for management. J Clin Oncol 8: 1424–1441

    PubMed  CAS  Google Scholar 

  11. Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E, Bauters F, Fenaux P (1993) Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 7: 1315–1323

    PubMed  CAS  Google Scholar 

  12. Vadhan Raj S, Keating M, LeMaistre A, Hittelman WN, McCredie K, Trujillo JM, Broxmeyer HE, Henney C, Gutterman JH (1987) Effects of recombinant human granulocyte — macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317: 1545–1552

    Article  PubMed  CAS  Google Scholar 

  13. Schuster MW (1993) Will cytokines alter the treatment of myelodysplastic syndrome? Am J Med Sciences 305: 72–78

    Article  CAS  Google Scholar 

  14. Mertelsmann R, Thaler H, To L et al. (1980) Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood 56: 773–781

    PubMed  CAS  Google Scholar 

  15. Armitage JO, Dick FR, Needleman SW, Burns CP (1981) Effect of chemotherapy for the dysmyelopoietic syndrome, Cancer Treat Rep 65: 601–605

    PubMed  CAS  Google Scholar 

  16. Tricot G, Boogaerts MA (1986) The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. Br J Haemat 63: 477–483

    Article  CAS  Google Scholar 

  17. Fenaux P, Lai L, Jouet JP, Pollet JP, Bauters F (1988) Aggressive chemotherapy in adult primary myelodysplastic syndromes. Blut 57: 297–302

    Article  PubMed  CAS  Google Scholar 

  18. Aul C, Schneider W (1989) The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes. Cancer 64: 1812–1818

    Article  PubMed  CAS  Google Scholar 

  19. Büchner T, Hiddemann W, Blasius S et al. (1990) The role of chemotherapy intensity and duration. Two studies of the AMLCG. In: Büchner T, Schellong G, Hiddemann W, Ritter J (eds) Acute Leukemias II. Springer Verlag, Heidelberg Berlin: 261–266

    Google Scholar 

  20. Cheson BD (1992) Chemotherapy and bone marrow transplantation for myelodysplastic syndromes. Sem Oncol 19: 85–94

    CAS  Google Scholar 

  21. Appelbaum FR, Barrall J, Storb R et al. (1990) Bone marrow transplantation for patients with myelodysplasia. Ann Int Med 112: 590–597

    Article  PubMed  CAS  Google Scholar 

  22. de Witte T, Zwaan F, Hermans J, Vernant J, Kolb H, Vossen J, Lönnqvist B, Beelen D, Ferrant A, Gmür J, Liu Yin J, Troussard X, Chan J, van Lint M, Gratwohl A for the Working Party on Leukaemia (1990) Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantatioin Group ( EBMTG ). Br J Haemat 74: 151–155

    Google Scholar 

  23. Ratanatharathorn V, Karanes C, Uberti J, Lum LG, de Planque MM, Schultz KR, Cronin S, Dan ME, Mohamed A, Hussein M, Sensenbrenner LL (1993) Busulfanbased regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood 81: 2194–2199

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. W. Hiddemann
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Innere Klinik und Poliklinik (Tumorforschung) Westdeutsches Tumorzentrum Essen, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen, Deutschland

    Siegfried Seeber  & Jochen Schütte  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Hiddemann, W. (1995). Myelodysplastische Syndrome. In: Seeber, S., Schütte, J. (eds) Therapiekonzepte Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10494-1_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10494-1_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-58586-2

  • Online ISBN: 978-3-662-10494-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation